1. Home
  2. GMM vs MREO Comparison

GMM vs MREO Comparison

Compare GMM & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.52

Market Cap

60.9M

Sector

N/A

ML Signal

HOLD

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.32

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
MREO
Founded
2017
2015
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.9M
52.5M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
GMM
MREO
Price
$1.52
$0.32
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$1.50
AVG Volume (30 Days)
90.0K
1.3M
Earning Date
01-09-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
N/A
$6,000.20
Revenue Next Year
N/A
$34.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.20
52 Week High
$3.39
$2.94

Technical Indicators

Market Signals
Indicator
GMM
MREO
Relative Strength Index (RSI) 66.82 37.87
Support Level $1.41 $0.32
Resistance Level $1.62 $0.42
Average True Range (ATR) 0.13 0.03
MACD 0.04 0.00
Stochastic Oscillator 96.08 21.66

Price Performance

Historical Comparison
GMM
MREO

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: